October 17, 2024
Alkermes to Report Third Quarter Financial Results on October 24, 2024
September 25, 2024
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
September 23, 2024
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep E...
Jed Rosenbaum on the importance of access to treatment this National Recovery Month.
Katie Joyce shares her perspective on the importance of building an inclusive workplace.
Now in its 16th year, Alkermes’ employees got to work volunteering for Alkermes in Action.
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.